FDA questions studies of Genentech drug for cancer (The Arizona Republic)
Regulators say it's unclear whether the blockbuster brain cancer drug Avastin is effective.

FDA questions studies of Genentech drug for cancer (San Francisco Chronicle)
Federal health regulators said Friday it's unclear whether Genentech's blockbuster cancer drug Avastin significantly shrinks the deadliest type of brain tumor. The Food and Drug Administration is reviewing the company's drug for patients with recurring...

Editorials Respond To Court Ruling That FDA Actions On Plan B Contraceptive Tainted By Politics (Medical News Today)
Two newspapers published editorials in response to a federal judge's recent order that FDA reconsider age restrictions on nonprescription sales of the emergency contraceptive Plan B and that FDA allow nonprescription sales to women ages 17 and older within 30 days. Summaries appear below.